Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESC 2017: Renal-Denervation Redux? Medtronic Plans A New Pivotal Study Following Positive Data

Executive Summary

Medtronic is re-upping its investments into renal denervation to treat hypertension after interim results were positive from a study testing the device procedure in patients not taking antihypertensive drugs. The firm announced it is launching a new pivotal study, more than three-and-a-half years after its last pivotal trial in the space failed.

Advertisement

Related Content

Medtronic Confident Renal Denervation Trial Will Work This Time
Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific
The First Sham-Controlled PCI Trial In Stable Patients
Renal Denervation Round 2: Medtronic, Boston Sci Move Ahead With Studies
Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint

Topics

Advertisement
UsernamePublicRestriction

Register

MT105376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel